Nexus Pharmaceuticals Receives Successful FDA Inspection of Pharmaceutical Manufacturing Facility
8 May 2023 - - US-based Nexus Pharmaceuticals, Inc., a sterile manufacturer in the pharmaceutical industry, said its pharmaceutical manufacturing facility in Pleasant Prairie, Wisconsin, was successfully inspected by the Food and Drug Administration, which will allow Nexus to begin commercial operations.

The Pleasant Prairie facility, which spans more than 84,000 square feet, is equipped with state-of-the-art isolator technology and adheres to the highest current good manufacturing practice standards.

The facility will produce a range of injectable medications, providing hospitals and clinicians access to safe, affordable, and critical-need medications.

The rigorous FDA approval process ensures that facilities meet strict safety and quality standards. Nexus Pharmaceuticals, Inc. plans to manufacture a number of NDAs and ANDAs from the Wisconsin-based facility to bring innovative products as well as supply chain durability to the US healthcare system.

The leadership, regulatory, and business functions will remain in the Illinois headquarters facility.

Nexus Pharmaceuticals, Inc., a US-based healthcare company and certified diverse supplier, specializes in innovative processes to make difficult-to-manufacture specialty and generic drugs that are easier to use, less labor-intensive, and more streamlined in practice.

Nexus ensures that its high-quality FDA-approved drugs fulfill a critical unmet medical need and deliver dependable life-saving treatment options when and where they're needed most. For more information about Nexus Pharmaceuticals and its manufacturing facility in Wisconsin.